Pharma 2020 has activated Russian biomanufacturing tech market says GE Healthcare

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Ge healthcare life, Russia

Government efforts to encourage local drug production have “activated” the Russian biomanufacturing technology market according to GE Healthcare.

On Thursday R-Pharm opened the first facility in Russia to use GE’s Flex Factory platform. The plant - in Yaroslavl - will manufacture biologics and biosimilars for local and international markets.

The opening came six years after R-Pharm bought the platform from Xcellerex – the developer of FlexFactory which GE acquired in 2012​ – although system installation took less than a year according to Andrei Demurin, Director of GE Healthcare Life Sciences in Russia.

The decision was made to accommodate the FlexFactory into an existing building. Consequently, there was the additional need and effort to dismantle and remove old equipment housed in the selected building.

He added that: “With all this preparative work complete, in early 2015 the installation of the FlexFactory began. Approximately 12 months later the commissioning process saw the first engineering start-up of the Flex Factory in March 2016.”

R-Pharm’s set up includes two 2,000L Xcellerex XDR bioreactors according to Demurin who said the firm will use them to make therapies for autoimmune diseases and cancer. He was unable to disclose how much R-Pharm had paid for the system.

FlexFactory bioreactors at R-Pharm facility in Yaroslavl, Russia
R-Pharm facility in Yaroslavl, Russia

2020 vision

At the opening ceremony, Sergey Tsyb, Deputy Minister of Industry and Trade of the Russian Federation, said: "Modern technologies have an important role to play for Russian biopharmaceutical companies developing new products within the national Pharma-2020 program​.”

This was echoed by Demurin who told us the Pharma 2020 policy – which encourages international drug firms to make products in Russia – has had an impact on demand for biomanufacturing technologies.

We definitely see market activation, foreign companies are making positive steps to achieve greater local presence in 2017-2018.

We are seeing a drive to increase local production of strategic medicines including mAbs, blood factors, and vaccines, which is supporting the move to full cycle production​.”

He added that: “The industry is moving forward from clinical research to biomolecule production, which is driving the need for expansion of manufacturing capacity and or re-equipment​.”

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more